ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TMDX TransMedics Group Inc

127.99
3.55 (2.85%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
TransMedics Group Inc NASDAQ:TMDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.55 2.85% 127.99 126.82 129.50 129.66 123.9182 125.00 1,577,193 01:00:00

TransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference

28/07/2021 9:05pm

PR Newswire (US)


TransMedics (NASDAQ:TMDX)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more TransMedics Charts.

ANDOVER, Mass., July 28, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a virtual fireside chat at the upcoming Canaccord Genuity 41st Annual Growth Conference. The fireside chat will take place on Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time.

(PRNewsfoto/TransMedics, Inc.)

Event: Canaccord Genuity 41st Annual Growth Conference
Date: Wednesday, August 11, 2021
Time: 4:30 p.m. ET

A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. 

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-participate-in-the-canaccord-genuity-41st-annual-growth-conference-301343547.html

SOURCE TransMedics Group, Inc.

Copyright 2021 PR Newswire

1 Year TransMedics Chart

1 Year TransMedics Chart

1 Month TransMedics Chart

1 Month TransMedics Chart

Your Recent History

Delayed Upgrade Clock